These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 25162417)
21. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition. Han Q; Lin L; Zhao B; Wang N; Liu X Biochem Biophys Res Commun; 2018 Jun; 500(4):839-845. PubMed ID: 29704504 [TBL] [Abstract][Full Text] [Related]
23. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612 [TBL] [Abstract][Full Text] [Related]
24. Periostin responds to mechanical stress and tension by activating the MTOR signaling pathway. Rosselli-Murai LK; Almeida LO; Zagni C; Galindo-Moreno P; Padial-Molina M; Volk SL; Murai MJ; Rios HF; Squarize CH; Castilho RM PLoS One; 2013; 8(12):e83580. PubMed ID: 24349533 [TBL] [Abstract][Full Text] [Related]
25. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells. Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235 [TBL] [Abstract][Full Text] [Related]
26. mTORC2 is required for proliferation and survival of TSC2-null cells. Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669 [TBL] [Abstract][Full Text] [Related]
27. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent. Li C; Cui JF; Chen MB; Liu CY; Liu F; Zhang QD; Zou J; Lu PH Cancer Biol Ther; 2015; 16(1):34-42. PubMed ID: 25692620 [TBL] [Abstract][Full Text] [Related]
28. Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems. Andugulapati SB; Gourishetti K; Tirunavalli SK; Shaikh TB; Sistla R Phytomedicine; 2020 Nov; 78():153298. PubMed ID: 32781391 [TBL] [Abstract][Full Text] [Related]
29. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of 14-3-3 binding to Rictor of mTORC2 for Akt phosphorylation at Ser473 is regulated by selenoprotein W. Jeon YH; Park YH; Kwon JH; Lee JH; Kim IY Biochim Biophys Acta; 2013 Oct; 1833(10):2135-42. PubMed ID: 23680186 [TBL] [Abstract][Full Text] [Related]
31. Rictor/mammalian target of rapamycin complex 2 promotes macrophage activation and kidney fibrosis. Ren J; Li J; Feng Y; Shu B; Gui Y; Wei W; He W; Yang J; Dai C J Pathol; 2017 Aug; 242(4):488-499. PubMed ID: 28585302 [TBL] [Abstract][Full Text] [Related]
32. Investigating rutin as a potential transforming growth factor-β type I receptor antagonist for the inhibition of bleomycin-induced lung fibrosis. Karunarathne WAHM; Lee KT; Choi YH; Kang CH; Lee MH; Kim SH; Kim GY Biofactors; 2024; 50(3):477-492. PubMed ID: 38006284 [TBL] [Abstract][Full Text] [Related]
33. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice. Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438 [TBL] [Abstract][Full Text] [Related]
34. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts. Shu L; Houghton PJ Mol Cell Biol; 2009 Sep; 29(17):4691-700. PubMed ID: 19564418 [TBL] [Abstract][Full Text] [Related]
35. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Lee D; Sykes SM; Kalaitzidis D; Lane AA; Kfoury Y; Raaijmakers MH; Wang YH; Armstrong SA; Scadden DT Stem Cell Reports; 2014 Nov; 3(5):832-40. PubMed ID: 25418727 [TBL] [Abstract][Full Text] [Related]
36. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Guo Y; Kwiatkowski DJ Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687 [TBL] [Abstract][Full Text] [Related]
37. Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines. Lee SL; Chou CC; Chuang HC; Hsu EC; Chiu PC; Kulp SK; Byrd JC; Chen CS PLoS One; 2013; 8(6):e67149. PubMed ID: 23840605 [TBL] [Abstract][Full Text] [Related]
38. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma. Zhang X; Wang X; Xu T; Zhong S; Shen Z Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752 [TBL] [Abstract][Full Text] [Related]
39. Rictor, an mTORC2 Protein, Regulates Murine Lymphatic Valve Formation Through the AKT-FOXO1 Signaling. Banerjee R; Knauer LA; Iyer D; Barlow SE; Shalaby H; Dehghan R; Scallan JP; Yang Y Arterioscler Thromb Vasc Biol; 2024 Sep; 44(9):2004-2023. PubMed ID: 39087350 [TBL] [Abstract][Full Text] [Related]
40. PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12. Gan X; Wang J; Wang C; Sommer E; Kozasa T; Srinivasula S; Alessi D; Offermanns S; Simon MI; Wu D Nat Cell Biol; 2012 May; 14(7):686-96. PubMed ID: 22609986 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]